<DOC>
	<DOC>NCT02742987</DOC>
	<brief_summary>CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).</brief_summary>
	<brief_title>Clopidogrel Versus Ticagrelor in Type-2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>type 2 diabetes mellitus stable coronary disease coronary revascularization with PCI at least 1 month prior to recruitment acute coronary syndrome platelet count &lt;70x109/l active bleeding or bleeding diathesis history of intracranial bleeding gastrointestinal bleeding &lt;6 months cerebrovascular accident &lt;3 months history of malignancy concomitant need for oral anticoagulant therapy severe liver disease or chronic renal failure (glomerular filtration rate &lt;30 ml/min /1.73m2)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>